New Advances in Anticancer Therapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 20 October 2025 | Viewed by 94
Special Issue Editor
Interests: anti-cancer drug resistance; cancer testis antigen; micro RNAs; exosomes; signaling pathways; allergic inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains one of the leading causes of death worldwide. The existing cancer therapies suffer from severe side effects and drug resistance. Therefore, it is crucial to develop novel therapeutic strategies that can offer more effective and less toxic treatment options for cancer patients. Recent advances in anticancer therapy include RNA vaccines, CAR-T/NK cell therapy, gene editing, immune checkpoint inhibitors, gut microbiome, and antibody-drug conjugates, offering targeted and personalized treatments with improved efficacy and reduced side effects. In this Special Issue of Cells, I invite you to contribute, either in the form of original research articles, reviews, or perspective articles on all aspects related to the theme of “New Advances in Anticancer Therapy”. Expert articles describing functional, biochemical, or general aspects of anticancer therapy are highly welcome. Relevant topics include, but are not limited to:
- Anticancer drug resistance;
- Chemoimmunotherapy;
- Nanotechnology;
- RNA vaccines;
- Screening of novel anticancer drugs;
- Personalized anticancer therapy;
- Antibody-based immune-stimulating drugs;
- Combination of epigenetic drugs and immune checkpoint inhibitors.
Prof. Dr. Dooil Jeoung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody-based immunotherapy
- cell therapy
- personalized anticancer therapy
- RNA vaccines
- nanotechnology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
